| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥106.5B | ¥104.7B | +1.7% |
| Operating Income | ¥15.2B | ¥15.3B | -0.7% |
| Ordinary Income | ¥15.4B | ¥15.5B | -0.9% |
| Net Income | ¥10.6B | ¥10.4B | +2.4% |
| ROE | 4.7% | 4.5% | - |
FY2026 Q1 results showed modest growth with revenue of 106.5B yen (YoY +1.7%), while operating income of 15.2B yen declined slightly (YoY -0.7%). Ordinary income reached 15.4B yen (YoY -0.9%), and net income attributable to owners was 10.6B yen (YoY +2.4%). The company maintained a strong gross profit margin of 79.9%, reflecting high value-added product positioning in cosmetics and healthcare direct sales business. Operating margin stood at 14.3%, essentially unchanged from prior year. Total assets decreased to 273.6B yen from 282.5B yen, while equity declined modestly to 225.9B yen from 228.1B yen. The balance sheet remains highly liquid with cash and deposits of 170.2B yen representing 62.2% of total assets, supporting a current ratio of 561.2%. However, working capital efficiency presents significant concerns with inventory turnover of 409 days and receivables collection of 122 days, resulting in a cash conversion cycle of 389 days that warrants close monitoring.
Revenue increased 1.7% YoY to 106.5B yen, driven primarily by the core direct sales channel in cosmetics and healthcare products. According to segment disclosures, wholesale and overseas operations represent minimal portions of total revenue, confirming that domestic direct sales constitutes the primary revenue driver. The modest revenue growth of 1.7% lags the full-year forecast growth rate of 9.4%, suggesting acceleration is required in remaining quarters or Q1 represents a seasonal low base. Cost of sales increased proportionally, maintaining gross profit margin at 79.9%, indicating stable product pricing and mix. On the profit side, operating income of 15.2B yen declined 0.7% YoY as selling, general and administrative expenses of 69.8B yen remained elevated, absorbing most of the incremental gross profit. The operating margin of 14.3% held steady versus prior year, indicating expense discipline but limited operating leverage from revenue growth. Non-operating income and expenses contributed positively, with ordinary income of 15.4B yen showing only a minor 0.9% decline. The gap between ordinary income (15.4B yen) and operating income (15.2B yen) was minimal at 0.2B yen, suggesting limited contribution from financial income or equity method investments. Net income of 10.6B yen increased 2.4% YoY despite flat operating performance, primarily due to a lower effective tax rate of 31.1% versus prior period. No extraordinary items such as impairment losses, asset sales, or restructuring charges were disclosed. This represents a revenue up, profit down pattern at the operating level, with net income recovery driven by tax effects rather than core business improvement.
According to segment notes, the company operates primarily in direct sales of cosmetics and healthcare products, with wholesale and overseas sales representing immaterial portions that do not warrant separate disclosure. Therefore, the consolidated results effectively represent the core direct sales business performance. Operating margin of 14.3% for the consolidated entity reflects the profitability of this core direct sales segment.
[Profitability] ROE of 4.7% represents the return on equity, decomposed as net profit margin of 10.0% multiplied by asset turnover of 0.389 and financial leverage of 1.21 times. Operating margin of 14.3% remained flat YoY, while net profit margin of 10.0% improved modestly from the prior period. The relatively low asset turnover of 0.389 reflects working capital inefficiencies detailed below. [Cash Quality] Cash and deposits totaled 170.2B yen, providing short-term debt coverage of 4.1 times against current liabilities of 41.8B yen. However, quality concerns arise from receivables turnover of 122 days (DSO) and inventory turnover of 409 days (DIO), resulting in a cash conversion cycle of 389 days that indicates significant working capital absorption. [Investment Efficiency] Total asset turnover stood at 0.389 times, constrained by elevated working capital levels. Inventory represents a substantial portion of assets, with turnover efficiency requiring improvement. [Financial Health] Equity ratio of 82.6% exceeds prior year's 80.7%, reflecting conservative capitalization. Current ratio of 561.2% and quick ratio of 503.8% indicate exceptional liquidity. Debt-to-equity ratio of 0.21 times confirms minimal financial leverage. The balance sheet structure is highly conservative with substantial cash reserves offsetting working capital inefficiencies.
Cash and deposits decreased 11.0B yen YoY to 170.2B yen, representing a 6.1% decline from the prior period's 181.2B yen. This cash reduction occurred despite net income of 10.6B yen, suggesting cash outflows for dividends and working capital absorption exceeded earnings generation. Working capital movements show accounts payable increased 1.8B yen or 27.4% to 8.3B yen, indicating extended supplier payment terms or increased procurement volume. However, this favorable payables movement was insufficient to offset the substantial working capital tied up in inventory and receivables. The company's cash coverage of current liabilities remains strong at 4.1 times, providing substantial liquidity cushion. The balance sheet structure with 62.2% of assets in cash positions indicates conservative financial management, though the opportunity cost of holding such substantial non-earning cash warrants evaluation against alternative capital deployment strategies.
Ordinary income of 15.4B yen versus operating income of 15.2B yen shows non-operating net contribution of approximately 0.2B yen or 0.2% of revenue, indicating minimal reliance on non-operating items. The consistency between operating and ordinary income levels confirms that earnings are primarily derived from core business operations rather than financial income or equity method gains. Non-operating income represents a minimal portion of total profitability, with the small positive contribution likely comprising routine interest income on substantial cash deposits. The absence of cash flow statement data limits assessment of accruals quality, but the significant working capital inefficiency evidenced by 409-day inventory turnover and 122-day receivables collection raises concerns about earnings converting to cash. The calculated dividend payout ratio of 107.1% exceeds net income, suggesting either share count differences or that distributions rely partially on accumulated cash reserves rather than current period earnings alone.
Progress toward full-year guidance shows revenue of 106.5B yen achieving 23.7% of the annual forecast of 450.0B yen, below the standard Q1 benchmark of 25%. Operating income of 15.2B yen represents 30.4% of the full-year forecast of 50.0B yen, ahead of the 25% quarterly standard. Ordinary income of 15.4B yen achieves 30.7% of the 50.2B yen forecast, similarly above pace. Net income of 10.6B yen represents 31.2% of the 34.0B yen annual target, also exceeding quarterly expectations. The revenue progress rate lagging at 23.7% while profit metrics exceed 30% suggests either Q1 seasonal factors with revenue weighted toward later quarters, or improving profit margins anticipated in the original forecast. Full-year guidance assumes revenue growth of 9.4%, operating income growth of 4.6%, and ordinary income growth of 2.9%, indicating expectation of revenue acceleration with controlled expense growth. No forecast revisions were disclosed, indicating management maintains confidence in achieving targets despite Q1 revenue pacing below quarterly average.
Annual dividend of 52.0 yen per share represents the year-end distribution, with Q2 showing zero dividend indicating concentration of distributions at fiscal year-end. The calculated payout ratio of approximately 107.1% exceeds net income, suggesting either definitional differences in share count used for calculation or reliance on accumulated retained earnings and cash reserves to fund distributions. This elevated payout ratio warrants monitoring for sustainability, particularly given the absence of disclosed operating cash flow to confirm cash generation supports dividend policy. Total return ratio equals the payout ratio in absence of disclosed share buyback activity, indicating dividends comprise the sole shareholder return mechanism. The year-end concentrated dividend policy differs from quarterly distribution patterns and may reflect business seasonality or traditional payout timing preferences.
Inventory management risk represents the primary operational concern, with inventory turnover of 409 days indicating either significant product stockpiling, slow-moving items, or demand forecasting challenges. In cosmetics and healthcare direct sales, inventory obsolescence from product lifecycle changes or consumer preference shifts could necessitate write-downs. Receivables collection efficiency presents the second key risk, with DSO of 122 days suggesting extended credit terms in direct sales channels or collection difficulties that could impact cash realization and require allowance increases. Working capital absorption risk emerges from the combination of 409-day inventory turnover and 122-day receivables collection creating a 389-day cash conversion cycle that ties up substantial capital and constrains cash generation despite profitable operations, potentially limiting financial flexibility for growth investment or sustained high dividend distributions.
[Industry Position] (Reference - Proprietary Analysis) Profitability metrics show ROE of 4.7% exceeding the manufacturing industry median of 3.1% (2025-Q1, n=8), indicating above-median equity returns. Operating margin of 14.3% substantially exceeds the industry median of 6.8% (IQR: 2.9%-9.0%), confirming strong competitive positioning in margin realization. Net profit margin of 10.0% also surpasses the industry median of 5.9% (IQR: 3.3%-7.7%), reflecting superior cost structure or value-added positioning. Financial Health indicators show equity ratio of 82.6% well above the industry median of 43.9% (IQR: 28.4%-50.7%), demonstrating conservative capitalization relative to peers. Current ratio of 561.2% far exceeds the industry median of 1.87 times (IQR: 1.86x-2.23x), indicating exceptional liquidity but potentially inefficient capital deployment. Efficiency metrics reveal asset turnover of 0.389 times exceeds the industry median of 0.17 (IQR: 0.16-0.23), suggesting relatively efficient asset utilization despite working capital concerns. However, inventory turnover of 409 days compares unfavorably to the industry median of 498 days (IQR: 201-714 days), positioning near the middle of a wide range. Revenue growth of 1.7% lags the industry median of 13.2% (IQR: 2.5%-28.5%), indicating below-median top-line expansion. The company demonstrates superior profitability and financial strength relative to manufacturing peers, though growth momentum lags industry trends. (Industry: Manufacturing, N=8 companies, Comparison: 2025-Q1, Source: Proprietary analysis)
The company demonstrates exceptionally high gross margins of 79.9% and operating margins of 14.3% that substantially exceed manufacturing industry medians, indicating strong competitive positioning in cosmetics and healthcare direct sales with value-added products and pricing power. Cash conversion cycle of 389 days driven by 409-day inventory turnover and 122-day receivables collection represents the most significant operational inefficiency, warranting urgent management attention to working capital optimization that could unlock substantial cash generation from existing asset base. The combination of 82.6% equity ratio, 170.2B yen cash position, and payout ratio exceeding 100% indicates conservative balance sheet management with shareholder-friendly capital allocation, though dividend sustainability depends on improving operating cash flow generation that requires working capital efficiency gains in subsequent periods.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.